These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 1949899

  • 21. Investigations of the total flavonoids extracted from flowers of Abelmoschus manihot (L.) Medic against α-naphthylisothiocyanate-induced cholestatic liver injury in rats.
    Yan JY, Ai G, Zhang XJ, Xu HJ, Huang ZM.
    J Ethnopharmacol; 2015 Aug 22; 172():202-13. PubMed ID: 26133062
    [Abstract] [Full Text] [Related]

  • 22. Disposition of antipyrine in patients with extensive metastatic liver disease.
    Robertz-Vaupel GM, Lindecken KD, Edeki T, Funke C, Belwon S, Dengler HJ.
    Eur J Clin Pharmacol; 1992 Aug 22; 42(5):465-9. PubMed ID: 1606991
    [Abstract] [Full Text] [Related]

  • 23. The effect of age on the oxidative metabolism of antipyrine by uninduced microsomal fractions of rat liver.
    Van Geel CA, Van Bezooijen CF.
    Mech Ageing Dev; 1990 Apr 09; 53(2):169-77. PubMed ID: 2342384
    [Abstract] [Full Text] [Related]

  • 24. Effect of deltamethrin on antipyrine pharmacokinetics and metabolism in rat.
    Anadón A, Martinez-Larrañaga MR, Díaz MJ, Bringas P, Fernandez MC.
    Arch Toxicol; 1991 Apr 09; 65(2):156-9. PubMed ID: 2059156
    [Abstract] [Full Text] [Related]

  • 25. The effect of indomethacin on hepatic drug-oxidizing capacity in the rat: trimethadione and antipyrine metabolism as an indicator.
    Tanaka E, Kobayashi S, Aramphongphan A, Kurata N, Oguchi K, Kuroiwa Y, Yasuhara H.
    J Pharmacobiodyn; 1985 Sep 09; 8(9):773-9. PubMed ID: 4087137
    [Abstract] [Full Text] [Related]

  • 26. Effect of age on the pharmacokinetics of antipyrine in calves.
    Janus K, Suszycka J.
    Res Vet Sci; 1996 May 09; 60(3):234-7. PubMed ID: 8735513
    [Abstract] [Full Text] [Related]

  • 27. Antipyrine metabolite formation and excretion in patients with chronic renal failure.
    Teunissen MW, Kampf D, Roots I, Vermeulen NP, Breimer DD.
    Eur J Clin Pharmacol; 1985 May 09; 28(5):589-95. PubMed ID: 4043202
    [Abstract] [Full Text] [Related]

  • 28. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW, van der Veen EA, Doodeman PJ, Breimer DD.
    Eur J Clin Pharmacol; 1984 May 09; 27(1):99-103. PubMed ID: 6489432
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment.
    Danhof M, Krom DP, Breimer DD.
    Xenobiotica; 1979 Nov 09; 9(11):695-702. PubMed ID: 119355
    [Abstract] [Full Text] [Related]

  • 31. Changes in metabolism and urinary excretion of antipyrine induced by aerobic conditioning.
    Villa JG, Bayon JE, González-Gallego J.
    J Sports Med Phys Fitness; 1999 Sep 09; 39(3):197-201. PubMed ID: 10573660
    [Abstract] [Full Text] [Related]

  • 32. The effect of malaria infection on antipyrine metabolite formation in the rat.
    Mansor SM, Ward SA, Edwards G.
    Biochem Pharmacol; 1991 Apr 15; 41(8):1264-6. PubMed ID: 2009102
    [Abstract] [Full Text] [Related]

  • 33. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
    Reimann G, Barthel B, Rockstroh JK, Spatz D, Brockmeyer NH.
    Int J Clin Pharmacol Ther; 1999 Nov 15; 37(11):562-6. PubMed ID: 10584978
    [Abstract] [Full Text] [Related]

  • 34. The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione.
    Ohashi K, Sakamoto K, Sudo T, Tateishi T, Harada K, Fujimura A, Ebihara A, Tanaka E.
    J Clin Pharmacol; 1991 Dec 15; 31(12):1132-6. PubMed ID: 1761736
    [Abstract] [Full Text] [Related]

  • 35. Effects of gomisin A on liver functions in hepatotoxic chemicals-treated rats.
    Maeda S, Takeda S, Miyamoto Y, Aburada M, Harada M.
    Jpn J Pharmacol; 1985 Aug 15; 38(4):347-53. PubMed ID: 4068375
    [Abstract] [Full Text] [Related]

  • 36. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition.
    Buters JT, Zysset T, Reichen J.
    Biochem Pharmacol; 1993 Sep 14; 46(6):983-91. PubMed ID: 8216358
    [Abstract] [Full Text] [Related]

  • 37. Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.
    Teunissen MW, Srivastava AK, Breimer DD.
    Clin Pharmacol Ther; 1982 Aug 14; 32(2):240-6. PubMed ID: 7094512
    [Abstract] [Full Text] [Related]

  • 38. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F, Almar M, Pozuelo M, Sansegundo D, González-Sastre M, González-Gallego J.
    J Gerontol A Biol Sci Med Sci; 1998 Jan 14; 53(1):M14-9. PubMed ID: 9467428
    [Abstract] [Full Text] [Related]

  • 39. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR, Egan JM, Dickinson TH, Carrum G.
    J Pharmacol Exp Ther; 1988 Mar 14; 244(3):994-9. PubMed ID: 3252045
    [Abstract] [Full Text] [Related]

  • 40. Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.
    Anadón A, Martinez-Larrañaga MR, Fernandez MC, Diaz MJ, Bringas P.
    Antimicrob Agents Chemother; 1990 Nov 14; 34(11):2148-51. PubMed ID: 2073104
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.